Platelet deposition on stainless steel, spiral, and braided polylactide stents

Summary Platelets play a key role in (sub)acute thrombotic occlusion after stenting. We examined the possible differences between biodegradable polylactide (PLA) and stainless steel (SS) stents in platelet attachment and morphology after whole blood perfusion. PLA stents of different configurations (spiral/braided) and polycaprolactone-polylactide (PCL-PLA)-coatings, or SS stents were implanted into a PVC tube (Ø 3.2 mm), with or without precoating of the tube with type-I collagen. PPACK (30 µM)-anticoagulated blood with 3H-serotonin prelabeled platelets was perfused (flow rate: 30 ml/min, 90 s) over the stents. Platelet deposition was assessed by scintillation counting and morphology by scanning electron microscopy (SEM). To examine coagulation activation, plasma prothrombin fragments (F1+2) were measured before and after the perfusion. Protein deposition on PLA/SS stents was assessed at augmented shear forces mimicking coronary flow (rate: 60 ml/min, 60 s) under minimal anticoagulation (PPACK 1 µM). More platelets deposited on PLA stents than on SS stents under all study conditions (p <0.03). Under anticoagulation (PPACK 30 µM) the generation of F1+2 remained unaltered. Under higher flow rate and limited anticoagulation SS stents accumulated 3.27 ± 0.75 µg and PLA stents 5.25 ± 1.74 µg of protein (Mean ± SD, p <0.95). Among all biodegradable stents, the braided PLA stent coated with PCL-PLA-heparin accumulated the fewest platelets (p <0.02). In SEM, signs of platelet activation on braided heparin-coated PLA stents, when compared with uncoated braided PLA/SS stents, appeared modest. In conclusion, PCL-PLAheparin coating of biodegradable stents may enhance their hemocompatibility, expressed by less platelet deposition. Nevertheless, materials, design, and coating techniques of biodegradable stents must be further developed.

[1]  R C Eberhart,et al.  In vitro hemocompatibility studies of drug-loaded poly-(L-lactic acid) fibers. , 2003, Biomaterials.

[2]  B. Nilsson,et al.  Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. , 2003, Journal of biomedical materials research. Part A.

[3]  M. Leon,et al.  Safety of an Aspirin-Alone Regimen After Intracoronary Stenting With a Heparin-Coated Stent: Final Results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) Study , 2003, Circulation.

[4]  Robert C. Eberhart,et al.  Expandable Bioresorbable Endovascular Stent. I. Fabrication and Properties , 2003, Annals of Biomedical Engineering.

[5]  U. Kalnins,et al.  Heparin-Coated Stent Placement for the Treatment of Stenoses in Small Coronary Arteries of Symptomatic Patients , 2003, Circulation.

[6]  Mary E. Russell,et al.  TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.

[7]  M. Eisenberg,et al.  Coated Stents for the Prevention of Restenosis: Part II , 2002, Circulation.

[8]  M. Bell,et al.  Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. , 2002, Journal of the American College of Cardiology.

[9]  P. Serruys,et al.  Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation: Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up , 2002, Circulation.

[10]  I. Penn,et al.  Bypass Surgery Versus Stenting for the Treatment of Multivessel Disease in Patients With Unstable Angina Compared With Stable Angina , 2002, Circulation.

[11]  A. Takeshita,et al.  Reduction in Neointimal Formation With a Stent Coated With Multiple Layers of Releasable Heparin in Porcine Coronary Arteries , 2002, Journal of cardiovascular pharmacology.

[12]  P. Gurbel,et al.  Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. , 2002, The Journal of invasive cardiology.

[13]  S. Asko-Seljavaara,et al.  Topically Administered Macromolecular Heparin Proteoglycans Inhibit Thrombus Growth in Microvascular Anastomoses , 2002, Thrombosis and Haemostasis.

[14]  Y. L. Chen,et al.  Growth inhibition of cultured smooth muscle cells by corrosion products of 316 L stainless steel wire. , 2001, Journal of biomedical materials research.

[15]  V. Hombach,et al.  Comparison of the heparin coated vs the uncoated Jostent--no influence on restenosis or clinical outcome. , 2001, European heart journal.

[16]  Pertti Törmälä,et al.  Biodegradation of the Copolymeric Polylactide Stent , 2001, Journal of Vascular Research.

[17]  P. Kovanen,et al.  Coimmobilized Native Macromolecular Heparin Proteoglycans Strongly Inhibit Platelet-Collagen Interactions in Flowing Blood , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[18]  P. Törmälä,et al.  A New Biodegradable Stent for the Pancreaticojejunal Anastomosis After Pancreaticoduodenal Resection: In Vitro Examination and Pilot Experiences in Humans , 2000, Pancreas.

[19]  A. Schömig,et al.  Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. , 2000, Circulation.

[20]  H. Peltoniemi.  Biocompatibility and Fixation Properties of Absorbable Miniplates and Screws in Growing Calvarium : An experimental study in sheep , 2000 .

[21]  Johan W. M. Heemskerk, Pia R. M. Siljander, Edouard M. B,et al.  Receptors and signalling mechanisms in the procoagulant response of platelets , 2000 .

[22]  WolfgangKübler,et al.  Heparin Inhibits Ligand Binding to the Leukocyte Integrin Mac-1 (CD11b/CD18) , 1999 .

[23]  R. Herrmann,et al.  Antithrombogenic Coating of Stents Using a Biodegradable Drug Delivery Technology , 1999, Thrombosis and Haemostasis.

[24]  P. Törmälä,et al.  Bioabsorbable self-reinforced poly-L-lactide, metallic, and silicone stents in the management of experimental tracheal stenosis. , 1999, Chest.

[25]  R E Vlietstra,et al.  ACC Expert Consensus document on coronary artery stents. Document of the American College of Cardiology. , 1998, Journal of the American College of Cardiology.

[26]  H Shimokawa,et al.  Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. , 1998, Journal of the American College of Cardiology.

[27]  P. Cahalan,et al.  Heparin coating of tantalum coronary stents reduces surface thrombin generation but not factor IXa generation , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[28]  G. Willems,et al.  Activation of blood coagulation at heparin-coated surfaces. , 1997, Journal of biomedical materials research.

[29]  T. Tammela,et al.  The biodegradable self-reinforced poly-DL-lactic acid spiral stent compared with a suprapubic catheter in the treatment of post-operative urinary retention after visual laser ablation of the prostate. , 1997, British journal of urology.

[30]  F. Van de Werf,et al.  Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. , 1997, Circulation.

[31]  E J Topol,et al.  Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. , 1997, Journal of the American College of Cardiology.

[32]  F. Neumann,et al.  Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis. , 1997, Coronary artery disease.

[33]  P. Siljander,et al.  Platelet-derived microparticles associate with fibrin during thrombosis. , 1996, Blood.

[34]  Robert G. Johnson,et al.  Neointimal thickening after severe coronary artery injury is limited by a short-term administration of a factor Xa inhibitor. Results in a porcine model. , 1996, Circulation.

[35]  P D Verdouw,et al.  Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. , 1996, Circulation.

[36]  A. Buchwald,et al.  Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. , 1995, Journal of the American College of Cardiology.

[37]  D. Waters,et al.  Decreased Platelet Deposition and Smooth Muscle Cell Proliferation After Intramural Heparin Delivery With Hydrogel‐Coated Balloons , 1994, Circulation.

[38]  P. Mustonen,et al.  Epinephrine Augments Platelet Recruitment to Immobilized Collagen in Flowing Blood - Evidence for a von Willebrand Factor-mediated Mechanism , 1996, Thrombosis and Haemostasis.

[39]  J. Feijen,et al.  The effect of protein adsorption on the anticoagulant activity of surface immobilized heparin. , 1996, Journal of biomaterials science. Polymer edition.

[40]  P. Romaniuk,et al.  Immobilization of heparin on polylactide for application to degradable biomaterials in contact with blood. , 1995, Journal of biomaterials science. Polymer edition.